In contrast to S1P receptors on lymphocytes, the authors also demonstrated that FTY720 did not desensitize vascular S1P receptors suggesting that S1P agonists that selectively target the vasculature and not the immune system may be promising new drugs against atherosclerosis (Keul et al., 2007). Here, MBTPS1 is linked to atherosclerosis.